Accelovance Expands Capabilities in Europe with Acquisition of Altair Clinical, Ltd.

Accelovance, Inc. announces acquisition of Altair Clinical, Ltd.,  a full service European clinical CRO and provider of global clinical CRO resourcing solutions to pharmaceutical, biotech, and medical device companies. To learn more, click on the link for Press Release.

Oncology Protocol Challenge

Are you working on an Early Phase Oncology protocol or study concept? Participate in the Accelovance Oncology Protocol Challenge!

What is the Accelovance Protocol Challenge?

Accelovance's Protocol Challenge is an opportunity for a confidential review and discussion of your protocol or concept document. Our experts will review your information and provide a summary of operational, therapeutic, and strategic considerations tailored to your protocol/study concept. This assessment is free of charge, with no obligation of future work. To learn more, click on the link to download an overview of Accelovance's Protocol Challenge as well as information on how to participate.


Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards “Best Contract Research Organization”

Panacea Pharmaceuticals Engages Accelovance For Clinical Development Of Its Novel Nanoparticle-Based Therapeutic Cancer Vaccine

Accelovance Expands Capabilities in Europe with Acquisition of Altair Clinical, Ltd.

Former VP, Oncology, from Pfizer and Otsuka Joins Accelovance to Augment Oncology Growth

Stephen Trevisan interview with CEO of PharmaVentures


World Vaccine Congress 2015
April 7-9, 2015 – Washington, DC

The Atlantic Vaccines & Immunotherapeutics Summit
May 7-8, 2015 – Bethesda, MD

Clinical Trials Phase I and Phase IIA Summit
May 7-8, 2015 – Boston, MA